Phase I Human Safety Studies of FGI-101-1A6 to Combat HINI Influenza Virus

reportActive / Technical Report | Accession Number: ADA607997 | Open PDF

Abstract:

FGI-101-1A6 is a broad spectrum anti-TSG101 monoclonal antibody demonstrating broad in vitro anti-viral activity against several strains of Influenza and HIV. Under this contract, Functional Genetics will complete Phase Ia Human Safety Studies and an efficacy study against HIV in primates. This report describes the status of the program to date as well as outline the activities to be performed in the next period.

Author(s):
Diaz, Leyla
Author Organization(s):
FUNCTIONAL GENETICS INC ROCKVILLE MD
Descriptive Note:
Final rept. 1 Nov 2010-31 Mar 2013
Supplementary Note:
The original document contains color images. DOI: 10.21236/ADA607997
Pagination:
0025

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Report Number(s):
ARO-58853-LS-DRP.1
Contract/Grant Number(s):
W911NF-11-C-0029
Monitor Series:
58853-LS-DRP.1, ARO
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_6_Net Centric; JCA_5.3.3_Develop Strategy; JCA_5.3.4_Develop Courses of Action; JCA_5.3.5_Analyze Courses of Action; JCA_3.2_Engagement; JCA_3_Force Application; JCA_6.4.1_Secure Information Exchange; JCA_3.2.2_Non-Kinetic Means; JCA_6.4_Information Assurance; JCA_6.1_Information Transport; JCA_1.4_Force Support; JCA_5.5.2_Task; JCA_5.5_Direct; JCA_6.3.3_Spectrum Management; JCA_8_Building Partnerships; JCA_1.4.2_Health Service Delivery
Communities of Interest:
Biomedical
Descriptor(s):
*MONOCLONAL ANTIBODIES, CLINICAL TRIALS, INFLUENZA VIRUS, PHARMACOKINETICS
Field(s)/Group(s):
Pharmacology
Keyword(s):
PE0310BJ
Report Date:
2013 Jun 20
Creation Date:
2014 Oct 06